Share

May 30, 2017; 88 (22) Article

Autologous hematopoietic stem cell transplantation in multiple sclerosis

A meta-analysis

Maria Pia Sormani, Paolo A. Muraro, Irene Schiavetti, Alessio Signori, Alice Laroni, Riccardo Saccardi, Gian Luigi Mancardi
First published April 28, 2017, DOI: https://doi.org/10.1212/WNL.0000000000003987
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
760

Share

This article has a correction. Please see:

Article Information

vol. 88 no. 22 2115-2122
DOI: 
https://doi.org/10.1212/WNL.0000000000003987
PubMed: 
28455383
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received October 6, 2016
  • Accepted in final form February 6, 2017
  • First Published April 28, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Maria Pia Sormani, PhD,
    2. Paolo A. Muraro, MD,
    3. Irene Schiavetti, PhD,
    4. Alessio Signori, PhD,
    5. Alice Laroni, MD,
    6. Riccardo Saccardi, MD and
    7. Gian Luigi Mancardi, MD
  1. Maria Pia Sormani, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Merck Serono, TEVA, Genzyme, Novartis, Biogen, Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Merck Serono, Biogen, TEVA, Genzyme, Roche, Novartis, GeNeuro

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Paolo A. Muraro, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Muraro has received travel support and speaker honoraria from Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis.

    Editorial Boards:

    1. Guest Editor, PLOS Medicine

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Funder: Medical Research Council Type of grant: Project Grant Title: Pathfinder: An experimental medicine study of the 18 kD translocator protein as a novel neuroimmunodulatory target for multiple sclerosis Duration: 3 years 2016-19

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Funder: UK Multiple Sclerosis Society / UK Stem Cell Foundation Type of grant: Collaborative Project Grant Title: A phase II trial of autologous mesenchymal stem cell transplantation in highly active multiple sclerosis ? Duration:2012-17 PI: Muraro Co-applicants: Chandran, Dazzi, Miller, Nicholas

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Irene Schiavetti, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Alessio Signori, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Alice Laroni, MD,
    6. Scientific Advisory Boards:

    1. (1) Sanofi (2) Merck

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) travel, Teva (2) speaker honoraria, Biogen (3)speaker honoraria, Teva (4) speaker honoraria, Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Biogen, funding to a workshop organized by me

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Riccardo Saccardi, MD and
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. honoraria for lecturing from Sanofi

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Gian Luigi Mancardi, MD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Honoraria for lecturing , travel expenses for attending meetings and finacial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva Pharmaceuticals

    Editorial Boards:

    1. Associate Editor of Neurological Sciences

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Honoraria for speaking activities from Companies (Biogen Dompe', Bayer Schering)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Italian Multiple Sclerosis Society (AISM) Grants 2001-R-38 and 2002-R-36

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Health Sciences (M.P.S., I.S., A.S.) and Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (A.L., G.L.M.), University of Genoa, Italy; Division of Brain Sciences (P.A.M.), Imperial College, London, UK; IRCCS Azienda Ospedaliera Universitaria San Martino-IST (A.L., G.L.M.), Genoa; and Cell Therapy and Transfusion Medicine Unit (R.S.), Careggi University Hospital, Firenze, Italy.
  1. Correspondence to Dr. Sormani: mariapia.sormani{at}unige.it
View Full Text

Article usage

Article usage: April 2017 to March 2020

AbstractFullPdfSource
Apr 2017431015Highwire
May 2017229817174Highwire
Jun 201714044886Highwire
Jul 20173891645Highwire
Aug 20172212332Highwire
Sep 20172571724Highwire
Oct 20172112115Highwire
Nov 20172091619Highwire
Dec 20172671713Highwire
Jan 20182163128Highwire
Feb 20182072318Highwire
Mar 20182793522Highwire
Apr 20182962418Highwire
May 20182392621Highwire
Jun 20183512419Highwire
Jul 20181941516Highwire
Aug 20181892220Highwire
Sep 20181321211Highwire
Oct 20182291514Highwire
Nov 20182261518Highwire
Dec 20181861416Highwire
Jan 20192102219Highwire
Feb 20191591212Highwire
Mar 2019142147Highwire
Apr 2019182159Highwire
May 20191311212Highwire
Jun 20197572Highwire
Jul 2019141117Highwire
Aug 20196696Highwire
Sep 2019961312Highwire
Oct 201911797Highwire
Nov 201912343Highwire
Dec 20199053Highwire
Jan 2020162105Highwire
Feb 202096119Highwire
Mar 202017573Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

More Online

CME Course

Related Articles

Topics Discussed

Alert Me